Condition: Acute Respiratory Distress Syndrome · ARDS · Sponsor: Direct Biologics, LLC
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
This description comes directly from the study's public registry record.
Bill Arana · 1-800-791-1021 · clinicalaffairs@directbiologics.com
Always discuss trial participation with your own doctor first.
| Direct Biologics Investigational Site | Phoenix, Arizona, United States | Recruiting |
| Direct Biologics Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| Direct Biologics Investigational Site | Davis, California, United States | Recruiting |
| Direct Biologics Investigational Site | Irvine, California, United States | Recruiting |
| Direct Biologics Investigational Site | Sacramento, California, United States | Recruiting |
| Direct Biologics Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| Direct Biologics Investigational Site | Jacksonville, Florida, United States | Recruiting |
| Direct Biologics Investigational Site | Boise, Idaho, United States | Recruiting |
| Direct Biologics Investigational Site | Iowa City, Iowa, United States | Recruiting |
| Direct Biologics Investigational Site | Silver Spring, Maryland, United States | Recruiting |
| Direct Biologics Investigational Site | Boston, Massachusetts, United States | Recruiting |
| Direct Biologics Investigational Site | Burlington, Massachusetts, United States | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05354141